Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Monalizumab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innate Pharma: Monalizumab Data From NeoCOAST-2 Presented At WCLC 2024
    Innate Pharma: Monalizumab Data From NeoCOAST-2 Presented At WCLC 2024

    09 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240908660298/en

    BUSINESSWIRE
    09 Sep 2024
    Share Share
    Innate to Present Lacutamab PTCL Phase 1b Design & ANKET Platform at ESMO 2022
    Innate to Present Lacutamab PTCL Phase 1b Design & ANKET Platform at ESMO 2022

    05 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220904005030/en

    BUSINESSWIRE
    05 Sep 2022
    Share Share
    AstraZeneca's novel checkpoint inhibitor flunks first phase 3
    AstraZeneca's novel checkpoint inhibitor flunks first phase 3

    02 Aug 2022

    // Nick Paul Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/astrazenecas-novel-checkpoint-inhibitor-flunks-first-phase-3-denting-partners-share-price

    Nick Paul Taylor FIERCEBIOTECH
    02 Aug 2022
    Share Share
    Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
    Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

    01 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220731005041/en

    BUSINESSWIRE
    01 Aug 2022
    Share Share
    Patient Dosed in Monalizumab Phase 3 Lung Cancer Trial Triggers $50M Payment
    Patient Dosed in Monalizumab Phase 3 Lung Cancer Trial Triggers $50M Payment

    29 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220428006062/en

    BUSINESSWIRE
    29 Apr 2022
    Share Share
    Innate Pharma: Monalizumab + Cetuximab & Durvalumab Shows Anti-Tumor Activity
    Innate Pharma: Monalizumab + Cetuximab & Durvalumab Shows Anti-Tumor Activity

    09 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211209005158/en

    BUSINESSWIRE
    09 Dec 2021
    Share Share